Putting science to work against COVID

Syngene has stepped up its efforts to fight COVID-19


As a predominantly science-based organization (our workforce of 5000 comprises 4200 scientists of which over 450 are PhDs) Syngene was quick to understand the complexity of the problems  posed by COVID-19.

At Syngene, we are committed to protecting our workforce, minimizing business disruptions, playing our part in improving human health, and contributing to the government’s initiatives to combat COVID-19. Keeping this in mind, we have adopted a three-pronged strategy to combat COVID-19: protect our employees and contractors, ensure business continuity and leverage our R&D capabilities to combat COVID-19.

The New Normal

COVID-19 is not going to go away in the immediate future. Syngene is adapting quickly to this ‘new normal’. 

COVID-19 Offerings

Syngene is providing a range of services in the areas of diagnostics as well as therapeutic and vaccine R&D.

Supporting The Community

Syngene has stepped up its efforts to fight COVID-19 by redirecting its scientific and technical capabilities...

Remdesivir Production

Syngene is a voluntary license holder from Gilead for manufacture and sale of Remdesivir for COVID-19 patients. Any queries regarding Remdesivir supply can be directed to our marketing and distribution partners Sun Pharma and Biocon Biologics.

Biocon Biologics helpline (for inquiries within Karnataka) : 1800 425 6286
Sun Pharma helpline (for pan India inquiries other than Karnataka) : 1800 103 1013

From April 21, 2021 to June 6, 2021, Syngene has manufactured and supplied 1,29,755 Remdesivir lyophilised injections to the State of Maharashtra through its distribution partners *.

*Information supplied in compliance of order dated 02.05.2021 issued by the Bombay High Court (Nagpur Bench) in Suo-Motu P.I.L. No.4 of 2020 (Court on its own motion vs. Union of India and Ors).